Clinical Trial

"Pseudo-scanner" MRI Sequences for the Detection of Bone Lesions in Multiple Myeloma

Study acronym: MM-ZTE-II
Recruiting
View on ClinicalTrials.gov →
Summary
Recent work has confirmed the diagnostic performance of pseudo-CT sequences for detecting osteolytic lesions. Their integration into whole body MRI (WB MRI) could transform the diagnostic approach to MM, by allowing a combined assessment of bone marrow involvement, tissue viability and osteolysis, during a single non-irradiating imaging examination. Since the preliminary work mentioned above, optimizations have been made to the pseudo-CT sequences, including the addition of deep learning (correcting noise in the images) and the correction of chemical shift artifact (linked to the coexistence of hydrated tissue and fatty tissue), which carry real hope of improving their diagnostic potential and accuracy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-15; most recent amendment 2026-04-23.
Status change: Not Yet Recruiting → Recruiting 2026-04-23
Trial Details
NCT Number NCT06988020
Lead Sponsor Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Collaborators: General Electric
Conditions Multiple Myeloma Bone Disease
Enrollment 45 participants
Start Date 2025-04-22
Primary Completion 2027-11 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-04-24